AC-340
AC-340 is a potent hybrid VDR agonist/HDAC inhibitor. AC-340 superinduces VDR target genes (e.g., CYP24A1) and inhibits HDAC6 (IC50 = 0.37 μM) with ~10-fold selectivity over HDAC2. AC-340 induces VDR hyperagonism by causing widespread protein hyperacetylation (e.g., tubulin and H3K9/K27), which leads to elevated H3K27 acetylation on VDR target genes. AC-340 can be used for melanoma cancer research[1].
Product Specifications
UNSPSC
12352005
Target
HDAC; Microtubule/Tubulin; VD/VDR
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Smiles
CCC(CC)(C1=CC=C(C=C1)OCCCC(NO)=O)C2=NC(C)=C(S2)CCC(C(C)(C)C)O
Molecular Formula
C26H40N2O4S
Molecular Weight
476.67
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC2; HDAC6
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MAGEB16, CT (MAGEB16, Melanoma-associated antigen B16, MAGE-B16 antigen) (Azide free) (HRP) discontinued